Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Gene correction reduces cutaneous inflammation and granuloma formation in murine X-linked chronic granulomatous disease.

Goebel WS, Mark LA, Billings SD, Meyers JL, Pech N, Travers JB, Dinauer MC.

J Invest Dermatol. 2005 Oct;125(4):705-10.

2.

Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous disease.

Petersen JE, Hiran TS, Goebel WS, Johnson C, Murphy RC, Azmi FH, Hood AF, Travers JB, Dinauer MC.

J Invest Dermatol. 2002 Mar;118(3):424-9.

4.
6.

Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.

Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC, Ganser A, Hoelzer D, Seger R, Grez M.

Hum Gene Ther. 1998 Jul 20;9(11):1561-70.

PMID:
9694155
7.
8.
10.

Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease.

Goebel WS, Pech NK, Dinauer MC.

Blood Cells Mol Dis. 2004 Nov-Dec;33(3):365-71.

PMID:
15528159
11.
12.
13.

Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy.

Cruz CR, Lam S, Hanley PJ, Bear AS, Langston C, Cohen AJ, Liu H, Martinez CA, Krance RA, Heslop HE, Rooney CM, Hanson IC, Bollard CM.

Clin Exp Immunol. 2013 Oct;174(1):89-96. doi: 10.1111/cei.12156.

14.

Gene therapy of chronic granulomatous disease.

Grez M, Becker S, Saulnier S, Knöss H, Ott MG, Maurer A, Dinauer MC, Hoelzer D, Seger R, Hossle JP.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S99-104.

PMID:
10933200
15.

Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.

Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D, Malech HL.

Blood. 2010 Jan 28;115(4):783-91. doi: 10.1182/blood-2009-05-222760. Epub 2009 Dec 1.

16.

Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.

Sadat MA, Dirscherl S, Sastry L, Dantzer J, Pech N, Griffin S, Hawkins T, Zhao Y, Barese CN, Cross S, Orazi A, An C, Goebel WS, Yoder MC, Li X, Grez M, Cornetta K, Mooney SD, Dinauer MC.

Gene Ther. 2009 Dec;16(12):1452-64. doi: 10.1038/gt.2009.96.

17.

Progress in gene therapy for chronic granulomatous disease.

Malech HL.

J Infect Dis. 1999 Mar;179 Suppl 2:S318-25. Review.

PMID:
10081502
18.

A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression.

Sokolic RA, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Linton GF, Li F, Gottesman MM, Malech HL.

Blood. 1996 Jan 1;87(1):42-50.

19.

Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, Haria S, Parsley KL, Kinnon C, Malech HL, Bueren JA, Grez M, Thrasher AJ.

Mol Ther. 2011 Jan;19(1):122-32. doi: 10.1038/mt.2010.226. Epub 2010 Oct 26.

20.

From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.

Stein S, Scholz S, Schwäble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Müller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson RG Jr, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kühlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M.

Hum Gene Ther Clin Dev. 2013 Jun;24(2):86-98. doi: 10.1089/humc.2013.019.

PMID:
23845071

Supplemental Content

Support Center